Self-expandable stented valve with glutaraldehyde-fixed cardiac xenograft treated by novel anticalcification protocols including immunologic modification for perventricular pulmonic valve implantation
© Kim et al. 2015
Published: 16 December 2015
The conventional glutaraldehyde (GA) fixation for cardiac xenograft causes dystrophic calcification, and there is also a significant immune reaction to the galactose-α-1,3 galactose β-1,4-N-acetylglucosamine (α-Gal), leading to calcification. So, future investigation should be redirected in the quest for the αGal-free long-lasting substitutes.
We made the αGal-free long-lasting stented valve which is comprised of self-expanding nitinol frame containing GA-fixed xenografts treated by our novel combined anticalcification protocol. The safety and efficacy of our stented valve were evaluated using large-animal in vivo perventricular pulmonic circulatory models.
Porcine cardiac xenografts were treated by decellularization, immunologic modification with alpha-galactosidase, space filler, GA fixation in organic solvent, and detoxification. The nitinol (Nikel-Titanium, shape memory alloy) frame is comprised of a braided wire that reverts to its original shape and locks the valve into position as deployed. We manufactured the stented valve with the porcine cardiac xenografts mounted on a nitinol frame. The stented valves were implanted in ovine pulmonary valve position via perventricular approach, and durability was evaluated for 18 months after implantation.
To 18 months after perventricular pulmonic valve implantation, evaluation of echocardiography and cardiac catheterization demonstrated good hemodynamic status and function of pulmonary valve, and good endothelialization resulted in no paravalvular leakage. Durability of the porcine cardiac xenografts was well preserved without calcification.
We demonstrated the safety and efficacy of the αGal-free long-lasting stented valve with our synergistic and simultaneous employment of multiple anticalcification therapies including immunologic modification with alpha-galactosidase. The future clinical study is warranted based on these promising preclinical results using large-animal in vivo perventricular pulmonic circulatory models.
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.